Dr. Aria Vazirnia, MD

Dr. Vazirnia practices at Xcell Surgery Center 2 LLC in Westlake Village, California.

Dr. Vazirnia's NPI, 1528449519, was assigned on June 15, 2015. Dr. Vazirnia graduated from UC San Diego School of Medicine in 2015. Dr. Vazirnia holds Massachusetts license 278408.

Dr. Vazirnia's primary practice is Xcell Surgery Center 2 LLC, at 32144 Agoura Rd, Westlake Village, CA 91361 in Ventura County. The practice phone is (805) 601-7772.

Dr. Vazirnia's primary practice is Xcell Surgery Center 2 LLC in Westlake Village, California. The medical group on file is Apex Dermatology. Dmand AI also links Dr. Vazirnia to 4 more medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vazirnia practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Vazirnia's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Vazirnia is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Vazirnia's licenses on file in 2 states: Massachusetts and California.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, corns and calluses, facial skin infection and itchy rashes among the conditions Dr. Vazirnia treats.

CMS data shows 1,382 Medicare services from Dr. Vazirnia across 11 procedure codes in 2024, for 360 Medicare patients. Medicare paid $66,068 for them. Every service was in an office.

CMS counts 360 Medicare patients who saw Dr. Vazirnia in 2024. The largest group is 65 to 74, with 176 patients. 75% of them have high cholesterol, and 63% have high blood pressure. Their average risk score is 0.94, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Vazirnia's median patient age at 53, with 61% women.

In 2024, Dr. Vazirnia wrote 323 Medicare Part D claims for 153 patients. 91% of them were for generic drugs. CMS names the drug for 202 of them, across 8 drugs with 11 or more claims each, at $3,353 in total drug cost. In 2023, CMS named 195 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Vazirnia for performance year 2024, reported as part of a group. Dr. Vazirnia accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 328 procedures of removal of skin lesions by Dr. Vazirnia, more than 83% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 14 papers to Dr. Vazirnia, published from 2013 to 2024. 2019 was the busiest year, with 3. The most frequent topics are Cosmetic Techniques, Face and Head and Neck Neoplasms. Dr. Vazirnia has published most often in Dermatol Surg. Dr. Vazirnia's most frequent co-authors are Philip R. Cohen, MD, Melissa Danesh, MD and Richard Rox Anderson, MD.

CMS Open Payments shows 230 general payments to Dr. Vazirnia from 31 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 56% of the total. Solta Medical, a division of Bausch Health US, LLC paid the most, $12,146.

Dr. Vazirnia graduated from UC San Diego School of Medicine in 2015.

Dr. Vazirnia is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.